Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. There are around eight million people in the U...
Stockhouse Media | November 6, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. In a July 22 research note, ROTH Capital Partners analyst Tony Butler reported that "encouraging data" from Marker Therapeutics Inc.'s (MRKR:NASDAQ) Phase I trial, TACTO...
Streetwise Reports | July 24, 2019 |

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its e...
Streetwise Reports | March 25, 2019 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...
Streetwise Reports | April 7, 2020 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Strategic Partnership Highlights Global Ambitions for NASH Therapy

The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. In a June 25 research note, H.C. Wainwright & Co. analyst Ed Arce reported that GENFIT SA (GNFT:NADSAQ; GNFT:EURO) outlicensed elafibranor for $228...
Streetwise Reports | June 27, 2019 |

Coverage Initiated on U.S.-Based Precision Therapy Developer

The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. In an Oct. 3 research note, analyst Andrew Fein reported that H.C. Wainwright & Co. initiated coverage on Blueprint Medicines Corp. (BPMC:NASDAQ) with a Buy rating and a $100 per ...
Streetwise Reports | October 9, 2019 |
1 2 3 4 5 6 7 8 9 10 ...